Lantern Pharma to Report First Quarter 2026 Financial Results on May 15

Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, announced that it will report its first-quarter 2026 operating and financial results via press release on May 15. The update will include financial results for the quarter ended March 31, 2026, along with operational updates regarding the company’s clinical trials and development of its proprietary artificial intelligence and machine learning platforms.

Lantern Pharma is known for leveraging AI and machine learning through its proprietary RADR platform to transform the development of cancer therapies. Its clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.

Additionally, withZeta.ai, Lantern’s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the Company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.

The upcoming financial report is a key event for investors and stakeholders, as it will provide insight into the company's financial health and progress in its clinical programs. The operational updates are particularly important given the company's focus on AI-driven drug development, which has the potential to accelerate the discovery and development of cancer therapies.

For more details, the full press release is available at https://ibn.fm/dVleQ. Latest news and updates relating to LTRN can be found in the company’s newsroom at https://ibn.fm/LTRN.